Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cancer therapies, today announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer. Dr. Freedman brings deep experience in oncology drug development and other therapeutic areas, and a track record of leading programs through all phases of development, regulatory approval and commercialization. Bronson Crouch, CEO of ...

DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil"), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced that Bronson Crouch, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference at 4:20PM ET on Thursday, June 5, 2025. A live webcast will be available using this weblink: https://wsw.com/webcast/jeff319/til/1708376. About Instil BioInstil Bio is a clinical-stage biopharmaceutical company f ...

Instil Bio, Inc. (TIL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earni ...

Instil Bio, Inc. (TIL) closed the last trading session at $26.75, gaining 108.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $118.67 indicates a 343.6% upside potential.The mean estimate comprises three short-term price targets with a standard deviation of $64.73. While the lowest estimate of $51 indicates a 90.7% increase from the current price level, the most optimistic analy ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

DALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced that they will jointly host an investor and research analyst breakfast in Chicago, Illinois on Saturday, May 31, 2025 at 8:00 to 9:30 am CT adjacent to the McCormick Convention Center. Instil and ImmuneOnco management, along with a key opinion leader in the field of immuno-oncology, will discuss the evolving PD-(L ...

Financial Performance - For the three months ended March 31, 2025, the net loss was $28.2 million, compared to a net loss of $24.3 million for the same period in 2024, representing an increase of $3.9 million [100]. - Total operating expenses for the three months ended March 31, 2025, were $30.6 million, an increase of $6.6 million from $24.0 million in the same period in 2024 [118]. - Cash used in operating activities for the three months ended March 31, 2025, was $4.2 million, compared to $14.4 million for the same period in 2024, indicating a significant reduction in cash outflow [140][141]. - The company has incurred significant operating losses and does not expect to generate revenue from product sales for several years [123]. Expenses Breakdown - Research and development expenses decreased to $5.4 million for the three months ended March 31, 2025, from $7.3 million in 2024, a reduction of $1.9 million [119]. - General and administrative expenses were $9.1 million for the three months ended March 31, 2025, down from $12.4 million in 2024, a decrease of $3.3 million [121]. - Restructuring and impairment charges increased to approximately $16.1 million for the three months ended March 31, 2025, compared to $4.3 million in 2024, an increase of approximately $11.8 million [121]. Cash and Investments - As of March 31, 2025, the company had cash, cash equivalents, restricted cash, marketable securities, and long-term investments totaling $111.8 million [100]. - As of March 31, 2025, the company had cash and cash equivalents of $15.4 million, restricted cash of approximately $1.0 million, marketable securities of $88.3 million, and long-term investments of $7.2 million, totaling $111.8 million [124]. - Cash provided by investing activities for the three months ended March 31, 2025, was $9.6 million, primarily from marketable securities redemptions [142]. Financing Activities - The company raised net cash proceeds of $339.0 million from its IPO in the first quarter of 2021, selling 920,000 shares of common stock [125]. - The company entered into a Term Loan Agreement for $85.6 million to refinance construction loans, with a fixed interest rate of 6.35% per annum [127]. - Cash provided by financing activities for Q1 2025 was $0.2 million, primarily from stock options exercise of $0.4 million, offset by loan closing costs of $0.2 million [143]. - Cash provided by financing activities for Q1 2024 was nil, indicating no financing activities during that period [144]. Future Outlook - The company expects to continue incurring net losses for the foreseeable future due to ongoing development efforts [100]. - The company plans to pursue additional therapeutic in-licensing or acquisition opportunities to expand its pipeline [101]. - The company plans to sell the Tarzana facility, which could extend its cash runway if successful [132]. Regulatory and Reporting Status - The company is classified as an "emerging growth company," allowing it to rely on certain exemptions from public company reporting requirements until at least December 31, 2026 [150]. - The company may continue to be a "smaller reporting company" if the market value of shares held by non-affiliates remains below $250 million or if annual revenue is less than $100 million [151]. - The company has opted to delay adopting new accounting standards until it is no longer classified as an emerging growth company [149]. - The company’s financial statements may not be comparable to those of companies that comply with new accounting pronouncements as of public company effective dates [149]. - The management's discussion and analysis is based on GAAP-compliant condensed consolidated financial statements, requiring estimates and assumptions that may differ from actual results [145]. - The company is not required to provide quantitative and qualitative disclosures about market risk due to its status as a smaller reporting company [152]. Product Development - The lead product candidate, AXN-2510/IMM2510, is a bispecific antibody targeting PD-L1 and VEGFs, currently in clinical trials for multiple solid tumor cancers [95]. - Over 100 patients have been enrolled in the Phase I trial of AXN-2510/IMM2510 as monotherapy for advanced solid tumors as of January 13, 2025 [97]. - The company made an upfront payment of $10.0 million to ImmuneOnco as part of a collaboration agreement, with potential future payments of up to $2.1 billion in milestones [134].

Financial Position - As of March 31, 2025, Instil Bio had total cash, cash equivalents, restricted cash, marketable securities, and long-term investments of $111.8 million, a decrease from $115.1 million as of December 31, 2024[3]. - Instil Bio's total assets decreased to $237.4 million as of March 31, 2025, from $263.6 million as of December 31, 2024[13]. - Instil Bio expects its current cash position to fund its operating plan beyond 2026[3]. Expenses - Research and development expenses for Q1 2025 were $5.4 million, down from $7.3 million in Q1 2024, representing a decrease of approximately 26%[4]. - General and administrative expenses decreased to $9.1 million in Q1 2025 from $12.4 million in Q1 2024, a reduction of about 27%[4]. - Restructuring and impairment charges increased significantly to $16.1 million in Q1 2025 from $4.3 million in Q1 2024, marking an increase of approximately 274%[4]. Net Loss - The net loss per share for Q1 2025 was $4.32, compared to $3.74 in Q1 2024, reflecting an increase of about 15%[6]. - Non-GAAP net loss per share for Q1 2025 was $1.32, down from $2.39 in Q1 2024, indicating an improvement of approximately 45%[6]. Clinical Trials - The ongoing Phase 1b/2 trial of AXN-2510/IMM2510 in combination with chemotherapy for 1L NSCLC in China is expected to provide initial clinical data in the second half of 2025[5]. - A U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy is anticipated to begin before the end of 2025, pending regulatory approvals[5].

Financial Outlook - The company will remain an emerging growth company until the earliest of December 31, 2026, or until total annual gross revenue reaches at least $1.235 billion[332]. - The company does not anticipate paying any cash dividends on its common stock in the foreseeable future, with capital appreciation being the sole source of gains[335]. - The effective tax rate may fluctuate, and the company may incur tax obligations in excess of accrued amounts due to various factors[348]. - The company has significant federal and state net operating loss carryforwards that could expire unused, potentially increasing future tax obligations[349]. Regulatory and Compliance Risks - The company is subject to the Foreign Corrupt Practices Act and similar laws, which could result in significant penalties if violated[351]. - Disruptions at the FDA and other government agencies could hinder the approval and commercialization of new products, negatively impacting the business[352]. - Average review times at the FDA have fluctuated, affecting the ability to bring new products to market[353]. - Changes in government funding and priorities could significantly impact the FDA's ability to process regulatory submissions, adversely affecting the company[354]. Economic and Political Conditions - Unfavorable global economic and political conditions could adversely affect the company's business, financial condition, or results of operations[355]. - A severe or prolonged economic downturn could weaken demand for the company's product candidates and affect capital raising efforts[355]. - Economic conditions resulting in a weakening of the U.S. dollar could increase the costs of clinical trials[355]. - Political disruptions, including international trade disputes, could strain collaborators and manufacturers, potentially disrupting clinical trials[355]. Clinical Trials and Research - The company is funding and expects to fund additional clinical trials in China related to AXN-2510/IMM2510 and AXN-27M/IMM27M[355]. - Future clinical trials may be conducted outside of the United States, posing risks due to political tensions between the U.S. and China[355]. Company Classification - The company is subject to increased costs and demands due to being a public company, which could negatively affect financial results[340]. - The company is classified as a smaller reporting company and is not required to provide certain market risk disclosures[457].